Detalhe da pesquisa
1.
Bexarotene leads to durable improvements in visual evoked potential latency: A follow-up study of the Cambridge Centre for Myelin Repair One trial.
Mult Scler
; : 13524585241233177, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38426437
2.
Surface-in pathology in multiple sclerosis: a new view on pathogenesis?
Brain
; 144(6): 1646-1654, 2021 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-33876200
3.
Clinician and patient experience of neurology telephone consultations during the COVID-19 pandemic.
Postgrad Med J
; 98(1161): 533-538, 2022 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37066507
4.
Determinants of therapeutic lag in multiple sclerosis.
Mult Scler
; 27(12): 1838-1851, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33423618
5.
Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
Brain
; 143(9): 2742-2756, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32947619
6.
Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab.
Mult Scler
; 26(9): 1093-1101, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31169059
7.
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
JAMA
; 321(2): 175-187, 2019 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30644981
8.
An abnormal periventricular magnetization transfer ratio gradient occurs early in multiple sclerosis.
Brain
; 140(2): 387-398, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28043954
9.
Visual outcome measures in clinical trials of remyelinating drugs.
BMJ Neurol Open
; 6(1): e000560, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38389586
10.
Early depressive symptoms and disability accrual in Multiple Sclerosis: a UK MS Register study.
Sci Rep
; 13(1): 8227, 2023 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37225828
11.
A real-world clinical validation for AI-based MRI monitoring in multiple sclerosis.
NPJ Digit Med
; 6(1): 196, 2023 Oct 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37857813
12.
Remyelination in humans due to a retinoid-X receptor agonist is age-dependent.
Ann Clin Transl Neurol
; 9(7): 1090-1094, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35587315
13.
Remyelination varies between and within lesions in multiple sclerosis following bexarotene.
Ann Clin Transl Neurol
; 9(10): 1626-1642, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36116011
14.
Amphetamine-associated seizures: clinical features and prognosis.
Epilepsia
; 52(2): 401-4, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21314677
15.
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.
Lancet Neurol
; 20(9): 709-720, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34418398
16.
Keratinocyte growth factor impairs human thymic recovery from lymphopenia.
JCI Insight
; 52019 05 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31063156
17.
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
Lancet Neurol
; 16(4): 271-281, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28209331
18.
The role of MRI in the evaluation of secondary progressive multiple sclerosis.
Expert Rev Neurother
; 16(2): 157-71, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26692498
19.
Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis.
J Neuroimmunol
; 271(1-2): 66-8, 2014 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24703099
20.
Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.
Drug Des Devel Ther
; 7: 131-8, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23494602